- Home
- ALF vs CAPR Comparison
ALF vs CAPR Comparison
Compare ALF & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALF
- CAPR
- Stock Information
- Founded
- ALF 2024
- CAPR 2005
- Country
- ALF United States
- CAPR United States
- Employees
- ALF N/A
- CAPR N/A
- Industry
- ALF
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALF
- CAPR Health Care
- Exchange
- ALF NYSE
- CAPR Nasdaq
- Market Cap
- ALF 360.5M
- CAPR 332.5M
- IPO Year
- ALF 2024
- CAPR N/A
- Fundamental
- Price
- ALF $10.04
- CAPR $18.62
- Analyst Decision
- ALF
- CAPR Strong Buy
- Analyst Count
- ALF 0
- CAPR 7
- Target Price
- ALF N/A
- CAPR $39.29
- AVG Volume (30 Days)
- ALF 38.9K
- CAPR 1.1M
- Earning Date
- ALF 01-01-0001
- CAPR 11-13-2024
- Dividend Yield
- ALF N/A
- CAPR N/A
- EPS Growth
- ALF N/A
- CAPR N/A
- EPS
- ALF N/A
- CAPR N/A
- Revenue
- ALF N/A
- CAPR $23,228,045.00
- Revenue This Year
- ALF N/A
- CAPR N/A
- Revenue Next Year
- ALF N/A
- CAPR $135.53
- P/E Ratio
- ALF N/A
- CAPR N/A
- Revenue Growth
- ALF N/A
- CAPR 65.33
- 52 Week Low
- ALF $9.96
- CAPR $2.90
- 52 Week High
- ALF $10.25
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- ALF N/A
- CAPR 51.78
- Support Level
- ALF N/A
- CAPR $17.02
- Resistance Level
- ALF N/A
- CAPR $20.03
- Average True Range (ATR)
- ALF 0.00
- CAPR 1.65
- MACD
- ALF 0.00
- CAPR -0.32
- Stochastic Oscillator
- ALF 0.00
- CAPR 51.39
About ALF CENTURION ACQUISITION CORP
Centurion Acquisition Corp is a blank check company.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.